Login / Signup

Intraosseous Spindle Cell/Epithelioid Rhabdomyosarcoma with TFCP2 Rearrangement: A Recent Recognized Subtype with Partial Response to Alectinib.

Ediel ValerioJorge Logan Furtado CostaNatália Moreno Perez FraileCaroline Haydn CredidioMárcio Ricardo Taveira GarciaCristovam Scapulatempo NetoFelipe D'Almeida Costa
Published in: International journal of surgical pathology (2022)
Rhabdomyosarcoma affects mainly pediatric patients and is currently classified into four categories: embryonal, alveolar, pleomorphic, and spindle cell/sclerosing. Recently, a molecular group of spindle cell/sclerosing rhabdomyosarcoma demonstrated new fusion transcripts involving FET -family genes with TFCP2 . In this report, we describe a rare case of spindle cell/sclerosing rhabdomyosarcoma in a 19-year-old woman, presenting as a destructive lesion involving the condyle of mandible. Next generation sequencing was performed, revealing a FUS::TFCP2 fusion and deletion of ALK gene. Alectinib therapy was initiated, which resulted in a favorable response for 4 months. However, the patient died due progression of the tumor. To make an accurate diagnosis and ensure appropriate patient management, it is necessary to be aware of this variant and use proper immunohistochemical stains when facing malignant mesenchymal bone lesions, expanding its differential diagnosis.
Keyphrases
  • single cell
  • cell therapy
  • rare case
  • stem cells
  • genome wide
  • high resolution
  • gene expression
  • dna methylation
  • mass spectrometry
  • transcription factor